Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. at toll-free phone 1-844-600-2237 or FDA at 1‐800-FDA-1088 or .

“During the quarter, we delivered numerous posters, presentations and publications on the potential of ATH434 as a disease modifying treatment in a variety of ... Vanderbilt University Medical Center ...

Caris Life Sciences ® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today ...

Among President Trump’s many immigration policies implemented since he took office, his plan for mass deportations has ...

In hearings Wednesday and Thursday, senators questioned President Trump's nominee for Secretary of Health and Human Services, ...

The poster titled “Preclinical and Translational Pharmacokinetics ... includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or ...

Here we go again. Some lawmakers in Washington state will just not give up on their quest for a state-run single-payer health ...

University of Cincinnati experts will present research at the International Stroke Conference 2025 in Los Angeles.

When combined with gemcitabine and nab-paclitaxel for the treatment of advanced ... GI meeting at ASCO-GI Abstract, and poster at ASCO-GI Poster. ImmunoMet is also pleased to announce that it has ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.